Gilead Sciences Inc

Q: How do I trade GILD on Bybit?

Click the Trade button above to explore available products for Gilead Sciences Inc on Bybit, including Stocks (real equity), Perpetuals (leveraged, 24/7), xStocks (wallet-based, 24/7), and CFDs. Each suits a different trading strategy. Product availability may vary.

Q: Does Gilead Sciences Inc pay dividends?

Gilead Sciences Inc's current dividend yield is shown in the Key Metrics section. Bybit Stocks holders receive dividend distributions when declared, while Perpetual holders receive equivalent adjustments via the funding rate.

Q: What is Gilead Sciences Inc's P/E ratio, and what does it mean?

Gilead Sciences Inc's P/E ratio is shown in the Key Metrics section, along with its percentile ranking relative to peers in the Biotechnology sector. A higher P/E typically reflects higher growth expectations, while a lower P/E may indicate undervaluation.

Q: What financial results has Gilead Sciences Inc recently released?

The most recent quarterly results, including revenue, operating income, and net profit, are shown in the Financials section. Historical trends are available via the interactive charts.

Q: Can I trade GILD 24/7 on Bybit?

{{ticker}} Perpetuals and xStocks are available for 24/7 trading. Stocks trading follows regular market hours, with limited pre-market and post-market sessions.

Q: What payment methods can I use to buy GILD?

You can fund your Bybit account by depositing crypto, including USDT, or using a credit/debit card. Stocks, Perpetuals, and CFDs are all settled in USDT.

Q: How does buying GILD on Bybit compare to using a traditional broker?

If Stocks trading is available for Gilead Sciences Inc, Bybit gives you direct equity ownership, including dividend eligibility, similar to a traditional broker. Bybit also offers leveraged derivative products, including Perpetuals and CFDs, as well as tokenized products such as xStocks, all in a single account.

GILD

www.gilead.com

Biotechnology

1m5m15m1h4h1d1w

About Gilead Sciences Inc

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to...

IndustryBiotechnologyHeadquarters333 LAKESIDE DR, FOSTER CITY, CAPrimary ExchangeNASDAQEmployees17,000Listing DateJan 22, 1992Websitewww.gilead.com

Key Metrics

$186.13B

15.7x

-$7.95B

-$8.45

-27.39%

-6.56%

0.00%

Corporate Actions

Earnings ReportSep 30, 2024

FY2024 Q3 earnings reported. Diluted EPS: $1.00.

Ex-DividendDec 13, 2024

Quarterly dividend of $0.77 per share. Ex-dividend date: December 13. Payable: December 30.

Earnings ReportDec 31, 2024

FY2024 Q4 earnings reported. Diluted EPS: $0.38.

Earnings ReportDec 31, 2024

FY2024 Q4 earnings reported. Diluted EPS: $1.41.

Ex-DividendMar 14, 2025

Quarterly dividend of $0.79 per share. Ex-dividend date: March 14. Payable: March 28.

Earnings ReportMar 31, 2025

FY2025 Q1 earnings reported. Diluted EPS: $1.04.

Ex-DividendJun 13, 2025

Quarterly dividend of $0.79 per share. Ex-dividend date: June 13. Payable: June 27.

Earnings ReportJun 30, 2025

FY2025 Q2 earnings reported. Diluted EPS: $1.56.

Ex-DividendSep 15, 2025

Quarterly dividend of $0.79 per share. Ex-dividend date: September 15. Payable: September 29.

Earnings ReportSep 30, 2025

FY2025 Q3 earnings reported. Diluted EPS: $2.43.

Ex-DividendDec 15, 2025

Quarterly dividend of $0.79 per share. Ex-dividend date: December 15. Payable: December 30.

Earnings ReportDec 31, 2025

FY2025 Q4 earnings reported. Diluted EPS: $6.78.

Earnings ReportDec 31, 2025

FY2025 Q4 earnings reported. Diluted EPS: $1.74.

Ex-DividendMar 13, 2026

Quarterly dividend of $0.82 per share. Ex-dividend date: March 13. Payable: March 30.

Earnings ReportMar 31, 2026

FY2026 Q1 earnings reported. Diluted EPS: $1.61.

Ex-DividendJun 15, 2026

Quarterly dividend of $0.82 per share. Ex-dividend date: June 15. Payable: June 29.

Earnings ReportJun 30, 2026

FY2026 Q2 earnings reported. Diluted EPS: -$8.45.

Ex-DividendSep 15, 2026

Quarterly dividend of $0.82 per share. Ex-dividend date: September 15. Payable: September 29.

FAQ about Gilead Sciences Inc

What is the current price of Gilead Sciences Inc?

›

The current price of GILD is shown in the price section above and updated in real time during regular trading hours. If you trade GILD Perpetuals on Bybit, pre-market, post-market, and overnight prices are also available.

How do I trade GILD on Bybit?

›

Does Gilead Sciences Inc pay dividends?

›

What is Gilead Sciences Inc's P/E ratio, and what does it mean?

›

What financial results has Gilead Sciences Inc recently released?

›

Can I trade GILD 24/7 on Bybit?

›

What payment methods can I use to buy GILD?

›

How does buying GILD on Bybit compare to using a traditional broker?

›

Disclaimer

The information contained herein is provided for informational purposes only and does not constitute investment, financial, trading, or other professional advice. Trading in digital assets and securities involves substantial risk of loss, including the possible loss of all principal invested. The value of digital assets and securities may be highly volatile, and past performance is not indicative of future results. Market data displayed is sourced from third-party data providers and may be subject to delays or inaccuracies. Bybit does not warrant the accuracy, completeness, or timeliness of any information displayed. All investment decisions are made solely at the investor's own risk. Independent due diligence and consultation with a licensed financial advisor are strongly recommended before making any investment decision.

Trade GILD

Markets’ Eyes on the FED: FED Member Goolsbee on Inflation, Bessent on Warsh!

32m ago

US Dollar: Oil-driven support as Fed seen hiking – ING

Financia lJuice2h ago

Experts agree: Further US Dollar’s upside hinges on upcoming data and not hawkish Fed prospects

Financia lJuice3h ago

Federal Reserve's Goolsbee: If there is solid evidence that inflation is coming back down to 2%, I have no objection to rate cuts

PANews3h ago

Gold: Range-bound outlook with Fed headwinds – ING

Financia lJuice4h ago